In line with this notion, the antiproliferative effect of a derivative of the type 1 oxa-3-azaspiro[5.5]undecane has been observed through the modulation of the JAK2/STAT3 pathway in hepatocellular carcinoma and breast cancer cells, regardless of estrogen receptor expression status [11,12]. Here, STAT3 is linked to breast carcinoma.